MedGadget Editorial Team - MedGadget

Healthium and Romsons reported bid for BL Lifesciences stake featured graphic

Healthium, Romsons in Race to Acquire 70–80% Stake in BL Lifesciences at Up to ₹2,000 Crore Valuation

Healthium and Romsons are reported to be bidding for a 70-80% stake in BL Lifesciences at a valuation of up to Rs 2,000 crore. What is known so far.

October 6, 2026

GE HealthCare acquisition of SOFIE Biosciences for 945 million dollars featured graphic

Medical Device

GE HealthCare to Acquire SOFIE Biosciences for $945 Million in Major Radiopharma Expansion

GE HealthCare will buy SOFIE Biosciences for $945 million in cash, adding 15 PET radiopharmaceutical sites and 21 cyclotrons. Close expected in H1 2027.

October 6, 2026

Alector AL050 Genentech Roche brain-penetrant Parkinsons therapy licensing deal featured graphic

Pharmaceutical

Roche Bets Up to $1.27 Billion on Alector’s Brain-Penetrating Parkinson’s Therapy AL050

Genentech, part of Roche, licenses Alector AL050, a brain-penetrant GCase enzyme for Parkinson's, in a deal worth up to $1.27 billion.

October 6, 2026

Abbott CardioMEMS HF System and CardioGuide HF app FDA approval featured graphic

Medical Device

Abbott Gets FDA Approval for CardioMEMS HF System Upgrade With CardioGuide HF App

FDA approves new CardioMEMS HF System capabilities. The CardioGuide HF app lets patients see pulmonary artery pressure when their care team enables it.

October 6, 2026

Branded card reading Samfara Buys Danish Controlled-Substance API Maker, Chr. Olesen Synthesis

Pharmaceutical

Samfara Acquires Chr. Olesen Synthesis to Expand Pharmaceutical API Business

Samfara completed its first investment, buying Danish controlled-substance API maker Chr. Olesen Synthesis. What the plant makes and why it matters.

October 5, 2026

Branded card reading Replimune Launches Tudriqev in the US for Advanced Melanoma

Pharmaceutical

Replimune Launches TUDRIQEV in US for Advanced Melanoma Following FDA Approval

Tudriqev, used with nivolumab, is now available in the US for advanced melanoma after PD-1 therapy, following accelerated FDA approval.

October 5, 2026

Branded card reading Datroway plus Ivonescimab: The Science Behind the Combination

Pharmaceutical

Datroway Plus Ivonescimab: What the TROP2 ADC and PD-1/VEGF Combination Aims to Do in Breast and Lung Cancer

Why pair an ADC with a PD-1/VEGF antibody? What Datroway and ivonescimab do, the TNBC data so far and what remains unproven.

October 5, 2026

Branded card reading TIL Healthcare Sri City Plant Blast Kills Five Workers

Pharmaceutical

TIL Healthcare Pharma Plant Blast in Andhra Pradesh’s Sri City Leaves Workers Dead and Injured

A boiler explosion at the TIL Healthcare unit in Sri City, Andhra Pradesh killed five workers and injured over 10 on 3 October; the cause is under probe.

October 3, 2026

Pharmaceutical

FDA Approves Lilly Jaypirca as First-Line CLL/SLL Treatment

FDA approved Lilly Jaypirca (pirtobrutinib) for previously untreated CLL/SLL without 17p deletion on 2 October, based on the BRUIN CLL-313 trial.

October 3, 2026

Medical Device

SkinStylus Microneedling Expands to Six European Markets

SkinStylus microneedling is now available in the UK, Ireland, Germany, France, Spain and Portugal as SkinHealth Systems expands the SteriLock device.

October 2, 2026